Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
| ▸ | NRP1 | O14786 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748477 | 0.83 | KCNH2 (0.53) | KCNH2WDR5CCR2PIK3C3KDM1A | |
| SCHEMBL4550972 | 0.82 | KCNH2 (0.54) | KCNH2WDR5CCR2PIK3C3KDM1A | |
| SCHEMBL2748212 | 0.80 | KCNH2 (0.70) | KCNH2 | |
| SCHEMBL2746927 | 0.70 | ACMSD (0.41) | — | |
| SCHEMBL2746854 | 0.67 | ACMSD (0.38) | KCNH2PIK3C3 | |
| SCHEMBL2747486 | 0.65 | KCNH2 (0.53) | KCNH2WDR5CCR2NRP1 | |
| SCHEMBL3908016 | 0.64 | HTR1D (0.40) | — | |
| SCHEMBL3902288 | 0.63 | ACMSD (0.41) | — | |
| SCHEMBL2747281 | 0.62 | KDM1A (0.55) | PTGES2KDM1A | |
| SCHEMBL25073319 | 0.62 | FABP4 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | KCNH2 4765/4885WDR5 2652/4885CCR2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.